Abstract: A quiet transformation is underway in Northern Europe. Lithuania, Latvia, and Estonia are joining forces to create the Baltic Biotech Hub, an ambitious regional initiative designed to achieve what each country alone cannot: critical mass. Through the Baltic Biotech Action Plan, launched under the BioConnect project, the three nations aim to align talent, infrastructure, funding, and regulation into one integrated life sciences ecosystem. Estonia contributes its globally recognised digital health systems and the Estonian Biobank, with 20% of citizens contributing genomic data. Latvia strengthens the alliance with deep expertise in organic synthesis and pharmaceutical manufacturing, anchored by institutions like the Institute of Organic Synthesis of Latvia. Meanwhile, Lithuania brings rapid growth in gene editing and multiomics, supported by major investments such as the €7 billion BIO CITY initiative.
Together, the Baltics are positioning themselves not just as emerging players, but as a unified biotech hotspot with global ambitions. Lithuania’s bold target of generating 5% of GDP from life sciences by 2030 reflects the region’s momentum, while Latvia’s expanding R&D funding and Estonia’s digital-first healthcare infrastructure create complementary strengths. Beyond funding and facilities, the Action Plan focuses on long-term capacity building, STEM education, talent attraction, and startup support. With streamlined regulation, compact decision-making systems, and strong public–private collaboration, the region offers a model of agility that larger European ecosystems often struggle to match. By amplifying their collective voice within the EU, the Baltic states aim to move from being overlooked innovators to influential contributors shaping Europe’s biotech future.
Read the full article here: https://www.ddw-online.com/how-a-new-action-plan-is-putting-the-baltics-on-the-biotech-map-40659-202602/
